• Norsk
  • English

Serum protein treatment selection biomarker for Prostate Cancer

Diagnostics; Cancer

Business opportunity

Prostate cancer (PCa) is the second most common cancer in men, with an estimated 1.1 million new cases and 307,000 deaths in 2012. Limitations in current tools for management of prostate cancer have resulted in over-diagnosis and costly overtreatment, which is affecting the outcomes and quality of life of men. There is a clear medical need and market opportunities for accurate, noninvasive, and practical tests for prostate cancer .

Tech description

Scientists at the University of Oslo have identified a novel blood based protein biomarker which is posed to greatly improve clinical management of prostate cancer, addressing the following unmet medical needs:
Treatment selection for high-risk locally advanced disease, selecting among radiotherapy and/or androgen deprivation therapy Improved risk stratification, identifying whether the disease is indolent or aggressive, and providing a risk of metastasis 


Priority US patent application filed. The patent application claims prognostic and predictive uses of the technology.

Business Partner

Jørund Sollid
Business Development Manager
Mobile: (+47) 93 42 35 39